GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » LT-Debt-to-Total-Asset

Serina Therapeutics (Serina Therapeutics) LT-Debt-to-Total-Asset : 0.10 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Serina Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.10.

Serina Therapeutics's long-term debt to total assets ratio declined from Dec. 2022 (1.96) to Mar. 2024 (0.10). It may suggest that Serina Therapeutics is progressively becoming less dependent on debt to grow their business.

Serina Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Serina Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics LT-Debt-to-Total-Asset Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
LT-Debt-to-Total-Asset
0.10 1.96

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
LT-Debt-to-Total-Asset 0.10 - 1.96 0.04 0.10

Serina Therapeutics LT-Debt-to-Total-Asset Calculation

Serina Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=1.68/0.858
=1.96

Serina Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=1.106/10.856
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics  (AMEX:SER) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Serina Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
Traded in Other Exchanges
2BO:Germany
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Website
https://www.serinatherapeutics.com
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024